
Feature|Articles|October 8, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
A Steadying Trajectory: Biopharma Review and Outlook
Author(s)Peter Young
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Although the pace of innovation has been strong for both pharmaceutical and biotech companies, the financing, M&A and stock market developments in the first half of 2026 for organizations in both sectors have broken from past trends in certain categories, both positively and negatively. Many of these trends would seem not to make sense on the surface, but they are logical if you carefully examine the underlying drivers.
Related to this article

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering.
Advertisement
Advertisement
